Detalhe da pesquisa
1.
A vaccine targeting mutant IDH1 in newly diagnosed glioma.
Nature
; 592(7854): 463-468, 2021 04.
Artigo
Inglês
| MEDLINE | ID: mdl-33762734
2.
Publisher Correction: Actively personalized vaccination trial for newly diagnosed glioblastoma.
Nature
; 566(7745): E13, 2019 02.
Artigo
Inglês
| MEDLINE | ID: mdl-30733620
3.
Actively personalized vaccination trial for newly diagnosed glioblastoma.
Nature
; 565(7738): 240-245, 2019 01.
Artigo
Inglês
| MEDLINE | ID: mdl-30568303
4.
Common T-Cell-Receptor Motifs and Features in Patients with Cytomegalovirus (CMV)-Seronegative End-Stage Renal Disease Receiving a Peptide Vaccination against CMV.
Int J Mol Sci
; 23(3)2022 Jan 18.
Artigo
Inglês
| MEDLINE | ID: mdl-35162953
5.
Patient-Derived Tumor Organoids for Guidance of Personalized Drug Therapies in Recurrent Glioblastoma.
Int J Mol Sci
; 23(12)2022 Jun 12.
Artigo
Inglês
| MEDLINE | ID: mdl-35743016
6.
Genetically Modified Cellular Therapies for Malignant Gliomas.
Int J Mol Sci
; 22(23)2021 Nov 26.
Artigo
Inglês
| MEDLINE | ID: mdl-34884607
7.
A vaccine targeting mutant IDH1 induces antitumour immunity.
Nature
; 512(7514): 324-7, 2014 Aug 21.
Artigo
Inglês
| MEDLINE | ID: mdl-25043048
8.
Perspectives of immunotherapy in isocitrate dehydrogenase-mutant gliomas.
Curr Opin Oncol
; 30(6): 368-374, 2018 11.
Artigo
Inglês
| MEDLINE | ID: mdl-30102604
9.
The promises of immunotherapy in gliomas.
Curr Opin Neurol
; 30(6): 650-658, 2017 Dec.
Artigo
Inglês
| MEDLINE | ID: mdl-28984704
10.
mTOR target NDRG1 confers MGMT-dependent resistance to alkylating chemotherapy.
Proc Natl Acad Sci U S A
; 111(1): 409-14, 2014 01 07.
Artigo
Inglês
| MEDLINE | ID: mdl-24367102
11.
Concepts in glioma immunotherapy.
Cancer Immunol Immunother
; 65(10): 1269-75, 2016 10.
Artigo
Inglês
| MEDLINE | ID: mdl-27460064
12.
Suppression of TDO-mediated tryptophan catabolism in glioblastoma cells by a steroid-responsive FKBP52-dependent pathway.
Glia
; 63(1): 78-90, 2015 Jan.
Artigo
Inglês
| MEDLINE | ID: mdl-25132599
13.
H3K27M neoepitope vaccination in diffuse midline glioma induces B and T cell responses across diverse HLA loci of a recovered patient.
Sci Adv
; 10(5): eadi9091, 2024 Feb 02.
Artigo
Inglês
| MEDLINE | ID: mdl-38306431
14.
NLGN4X TCR transgenic T cells to treat gliomas.
Neuro Oncol
; 26(2): 266-278, 2024 02 02.
Artigo
Inglês
| MEDLINE | ID: mdl-37715782
15.
The immunoglobulin superfamily ligand B7H6 subjects T cell responses to NK cell surveillance.
Sci Immunol
; 9(95): eadj7970, 2024 May 03.
Artigo
Inglês
| MEDLINE | ID: mdl-38701193
16.
2-hydroxyglutarate rides the cancer-immunity cycle.
Curr Opin Biotechnol
; 83: 102976, 2023 10.
Artigo
Inglês
| MEDLINE | ID: mdl-37515937
17.
Tumor-reactive T helper cells in the context of vaccination against glioma.
Cancer Cell
; 41(11): 1829-1834, 2023 11 13.
Artigo
Inglês
| MEDLINE | ID: mdl-37863064
18.
Dysfunctional dendritic cells limit antigen-specific T cell response in glioma.
Neuro Oncol
; 25(2): 263-276, 2023 02 14.
Artigo
Inglês
| MEDLINE | ID: mdl-35609569
19.
MHC class II-restricted antigen presentation is required to prevent dysfunction of cytotoxic T cells by blood-borne myeloids in brain tumors.
Cancer Cell
; 41(2): 235-251.e9, 2023 02 13.
Artigo
Inglês
| MEDLINE | ID: mdl-36638785
20.
The pre-existing T cell landscape determines the response to bispecific T cell engagers in multiple myeloma patients.
Cancer Cell
; 41(4): 711-725.e6, 2023 04 10.
Artigo
Inglês
| MEDLINE | ID: mdl-36898378